New hope for tough colon cancer: Triple-Drug attack shows promise
NCT ID NCT05672316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow the cancer's growth. About 28 adults will take part, and the study will first find the best dose and then check how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Can a new drug combo shrink Hard-to-Treat colorectal tumors?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?